Inhibition of platelet activation by clopidogrel in type II diabetes mellitus patients

Inhibition of platelet activation by clopidogrel in type II diabetes mellitus patients - clopi2008

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32343

Enrollment

Registered

2008-07-15

Start date

2009-03-03

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus / diabetes

Interventions

clopidogrel 75 mg per dag for one week

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. healthy controls (matched by age and gender) 2. type II DM patients, treated with oral bloodglucose lowering agents (biguanides or sulfonylurea derivates)

Exclusion criteria

Exclusion criteria: pregnancy; use of anti-epileptic drugs; use of acetylsalicylacid, NSAID, GPIIb-IIa antagonists, heparin or thrombolytica; known diabetic retinopathy; smoking; hypersensitivity to the drug substance or any component of the product; severe liverfunctiondisorder; active pathological bleeding such as peptic ulcer or intracranial hemorrhage; breastfeeding; surgery or dental operation 7 days prior or 7 days after the start of clopidogrel intake; galactose intolerance, lapp lactase deficiency or glucose galactose malabsorbtion

Design outcomes

Primary

Measure	Time frame
[1] ADP and collagen stimulated Ca2+ mobilization of platelets [2] ADP and collagen stimulated P-selectin expression on platelets	—

Secondary

Measure	Time frame
NVT	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)